Angiogenesis in non-small cell lung cancer

Seminars in Thoracic and Cardiovascular Surgery

Volumn 16, Issue 1, 2004, Pages 13-18

  D'Amico, Thomas A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CARBOPLATIN; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; CANCER TISSUE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG FATALITY; EARLY CANCER; HEMOPTYSIS; HUMAN; LUNG NON SMALL CELL CANCER; RISK ASSESSMENT; TISSUE DEGENERATION; TISSUE METABOLISM; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 2642519825     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2004.01.003     Document Type: Review

References (46)

1. Jemal A, Murray T, Samuels A, et al: Cancer statistics 2003. CA Cancer J Clin 53:5-26, 2003
2. Mountain CF: Revisions in the international system for staging lung cancer. Chest 111:1710-1717, 1997
3. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trials. BMJ 311:899-909, 1995
4. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatinum-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. New Engl J Med 350:351-360, 2004
5. D'Amico TA, Massey M, Herndon JE, et al: A biological risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with use of ten molecular markers. J Thorac Cardiovasc Surg 117:736-743, 1999
6. D'Amico TA, Aloia TA, Herndon JE, et al: Molecular biologic substaging in patients with stage I non-small cell lung cancer: Risk stratification according to gender and histologic subtype. Ann Thorac Surg 69:882-886, 2000
7. Brooks, KR, Harpole, DH, Joshi, MB, et al: Serum protein expression predicts recurrence in patients with early stage lung cancer after resection. Ann Thorac Surg (submitted).
8. Herbst RS, Fidler IJ: Angiogenesis and lung cancer: potential for therapy. Clin Cancer Res 6:4604-4606, 2000
9. Lau CL, D'Amico TA, Harpole DH: Staging and prognosis: Clinical and molecular prognostic factors and models for non-small cell lung cancer, in Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD (eds): Lung Cancer Principles and Practice (2nd Edition). Philadelphia, Lippincott, Williams and Wilkins, 2000, pp 602-611
10. Cox G, Jones JL, Walker RA, et al: Angiogenesis and non-small cell lung cancer. Lung Cancer 27:81-100, 2000
11. Vermulen PN, Gasparini G, Fox SB, et al: Quantification of angiogenesis in solid tumours: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A:2474-2484, 1996
12. Fox SB, Leek RD, Weekes MP, et al: Quantification and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkely count, and computer image analysis. J Pathol 177:272-283, 1995
13. Weidner N, Semple JP, Welch WR, et al: Tumour angiogenesis and metastatasis - correlation in invasive breast carcinoma. New Engl J Med 324:1-8, 1991
14. Saclarides TJ, Speziale NJ, Drab E, et al: Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 37:921-926, 1994
15. Aloia TA, Harpole DH, Reed CE, et al: Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 72:859-866, 2001
16. Tanigawa N, Amaya J, Matsumura M, et al: Extent of tumour vascularization correlates with prognosis and hematogenous metastasis in gastric carcinoma. Cancer Res 56:2671-2676, 1996
17. Hollingsworth HC, Kohn EC, Steinberg SM et al: Tumour angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33-44, 1995
18. Weidner N, Carroll PR, Flax J, et al: Tumour angiogenesis correlates with metastases in invasive prostate cancer. Am J Pathol 55:371-374, 1993
19. D'Amico TA, Massey M, Herndon JE, et al: A biological risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 117:736-743, 1999
20. D'Amico TA, Aloia TA, Herndon J E, et al: Molecular biologic substaging in patients with stage I non-small cell lung cancer: Risk stratification according to gender and histologic subtype. Ann Thorac Surg 69:882-886, 2000
21. Duarte IG, Bufkin BL, Pennington MF, et al: Angiogenesis a predictor of survival after surgical resection for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 115:652-965, 1998
22. Fontanini G, Vignati S, Bigini D, et al: Microvessel count predicts metastatic disease and overall survival in non-small cell lung cancer. J Pathol 177:57-63, 1995
23. Fontanini G, Lucchi M, Vignati S, et al: Angiogenesis as a prospectivc indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 89:881-886, 1997
24. Harpole DH, Richards WG, Herndon JE, et al: Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61:1470-1476, 1996
25. Imoto H, Osaki T, Taga S, et al: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115:1007-1011, 1998
26. Matsuyama K, Chiba Y, Sasaki M, et al: Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg 65:1405-1409, 1998
27. Offerson BV, Pfeiffer P, Hamilton-Dutoit S, et al: Patterns of angiogenesis in nonsmall-cell lung carcinoma. Cancer 91:1500-1509, 2001
28. Shijubo N, Kojima H, Nagata M, et al: Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech 60:186-198, 2003
29. Siegfried JM, Weissfeld LA, Luketich JD, et al: The clinical significance of hepatocyte growth factor for non-small cell lung cancer. Ann Thorac Surg 66:1915-1918, 1998
30. D'Amico TA: Molecular biologic staging of non-small cell lung cancer. J Thorac Cardiovasc Surg 123:409-410, 2002
31. Volm M, Koomagi R, Mattern J: PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 19:651-655, 1999
32. Decaussin M, Sartelet H, Robert C, et al: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188:369-377, 1999
33. Pastorino U, Andreola S, Tagliabue E, et al: Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol 15:2858-2865, 1997
34. Marrogi AJ, Travis WD, Welsh JA, et al: Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 6:4739-4744, 2000
35. Dy GK, Adjei AA: Novel targets for lung cancer therapy: Part II. J Clin Oncol 20:3016-3028, 2002
36. DeVore RF, Fehrenbacher L, Herbst RS, et al: A randomized phase II trial comparing rhumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc Am Soc Clin Oncol 19:485a, 2000 (abstr 1896)
37. Johnson DH, deVore R, Kabbinavar F, et al: Carboplatin (C) + paclitaxel (P) + rhuMab-VEGF(AVF) may prolong survival in advanced non-squamous lung cancer. Proc Am Soc Clin Oncol 20:315a, 2001 (abstr 1256)
38. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Am Soc Clin Oncol 22, 2003 (abstr 3646)
39. Herbst RS, Madden TL, Tran HT, et al: Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small cell lung cancer. J Clin Oncol 20:4440-4447, 2002
40. Wedge SR, Ogilvie DJ, Dukes M, et al: Chronic and acute effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on established human tumour xenografts. Proc Am Assoc Cancer Res 41:3610, 2000 (abstr 268)
41. Moser TL, Stack MS, Asplin I, et al: Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96:2811-2816, 1999
42. Dhanabal M, Ramchandran R, Waterman MJ, et al: Endostatin induces endothelial cell apoptosis. J Biol Chem 274:11721-11726, 1999
43. Boehm T, Folkman J, Browder T, et al: Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-440, 1997
44. DeMoraes ED, Fogler WE, Grant D, et al: Recombinant human angiostatin (rhA): A phase I clinical trial assessing safety, pharmacokinetics (PK) and pharmacodynamics. Proc Am Soc Clin Oncol 20:3a, 2001 (abstr 10)
45. Eder JP, Clark JW, Supko JG, et al: A phase I pharmacokinetic and pharmacodynamic trial of recombinant human endostatin. hy Proc Am Soc Clin Oncol 20:70a, 2001 (abstr 275)
46. Thomas JP, Schiller J, Lee F, et al: A phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin. Proc Am Soc Clin Oncol 20:70a, 2001 (abstr 276)